Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Verastem, Inc.NASDAQ: VSTM

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $38.22M rose 31.1% year over year, behind the +33.3% change in trailing-twelve-month research & development. Sequentially, it rose 20.7% from the prior quarter. Over 3 fiscal years it compounded at +31.4% a year.

Context

  • Research & development amounted to 370.7% of revenue in FY2025, down 442.6 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +31.1% toward the trailing-twelve-month pace of +33.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$38.22M+20.7% QoQ
Last fiscal yearDec 2025
$114.6M+40.9% YoY
LTMMar 2026
$123.67M+33.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.1%——
1 year+40.9%——
3-year CAGR+31.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
114.6M USD
Year-over-year change
+40.9%
4-year CAGR
+30.6%

Research & Development vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's LTM Mar 2026 research & development of $123.67M is the 4th highest of the 11 companies compared; the peer median is $91.94M.
  • Its year-over-year change of +33.3% is the 3rd highest of 10, against a peer median of -9.4%.
  • Research & development amounts to 249.4% of revenue for VSTM, versus a peer median of 382.5%.
VSTM Competitors Peer median
Research & Development for VSTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
BBOTBridgeBio Oncology Therapeutics Inc.LTM Mar 2026$140.37M +74.2%——
NUVBNuvation Bio Inc.LTM Jun 2026$128.85M +18.2%+9.4%75.8%
VSTMVerastem, Inc.LTM Mar 2026$123.67M +33.3%+31.4%249.4%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$116.62M -0.1%+21.2%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$79.09M -33.8%+0.5%473.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
ANLAdlai Nortye Ltd.LTM Jun 2024$56.93M —-15.5%877.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M -19.6%+9.2%6022.3%
Peer median (excluding VSTM) $91.94M-9.4%+5.1%382.5%

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.05M2.6M010M30.91M
Cost of Revenue00005.3M
Gross Profit2.05M2.6M010M25.62M
Gross Margin100.0%100.0%—100.0%82.9%
Research & Development39.35M50.56M61.36M81.33M114.6M
Selling, General & Admin24.12M24.98M30.73M43.62M81.15M
Operating Expenses63.46M75.53M92.08M124.96M195.75M
Depreciation & Amortization72K118K62K26K728K
EBITDA(61.16M)(71.56M)(83.17M)(125.86M)(207.61M)
EBITDA Margin-2978.9%-2756.4%—-1258.6%-671.6%
Operating Income(61.41M)(72.94M)(92.08M)(114.96M)(170.13M)
Operating Margin-2991.2%-2809.6%—-1149.6%-550.3%
Interest Income181K1.22M6.21M4.15M4.07M
Interest Expense9.97M2.14M4.14M4.56M1.14M
Other Income / Expenses(9.79M)(875K)4.72M(15.5M)(39.34M)
Income Before Tax(71.2M)(73.81M)(87.37M)(130.45M)(209.47M)
Pre-Tax Margin-3468.1%-2843.3%—-1304.5%-677.6%
Income Tax Expense000185K0
Net Income(71.2M)(73.81M)(87.37M)(130.64M)(209.47M)
Net Margin-3468.1%-2843.3%—-1306.4%-677.6%
EPS (Basic)(4.92)(4.57)(3.96)(3.66)(3.02)
EPS (Diluted)(4.92)(4.57)(3.96)(3.66)(3.02)
Weighted Avg Shares14.53M16.14M22.05M35.71M69.31M
Weighted Avg Shares (Diluted)14.53M16.14M22.05M35.71M69.31M

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.